Somatostatin receptor radionuclide therapy in neuroendocrine tumors.
177Lutetium-DOTATATE
PRRT
neuroendocrine tumors
peptide receptor radionuclide therapy
radiolabeled somatostatin analog
Journal
Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
08
02
2021
accepted:
10
02
2021
pubmed:
21
2
2021
medline:
14
1
2022
entrez:
20
2
2021
Statut:
ppublish
Résumé
Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review summarizes study data supporting the use of radiolabeled somatostatin analogs for the treatment of advanced NETs and highlights risks, including potential toxicities in specific populations. Key ongoing clinical trials, including randomized studies, are designed to better define the position of PRRT within the broader therapeutic landscape. Preclinical and early-phase human studies are focused on the development of novel somatostatin-receptor agonists and antagonists, new radionuclides, and radiosensitizing combination therapies.
Identifiants
pubmed: 33608483
doi: 10.1530/ERC-20-0360
pii: ERC-20-0360
pmc: PMC8118168
mid: NIHMS1699721
doi:
pii:
Substances chimiques
Organometallic Compounds
0
Radioisotopes
0
Receptors, Somatostatin
0
copper dotatate CU-64
0
Somatostatin
51110-01-1
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
R81-R93Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Références
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):934-946
pubmed: 31707430
Mol Imaging Biol. 2015 Jun;17(3):313-8
pubmed: 25319765
Neuroendocrinology. 2015;101(3):211-22
pubmed: 25765100
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1788-97
pubmed: 21553086
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):223-30
pubmed: 24233003
J Nucl Med. 2019 Mar;60(3):377-385
pubmed: 30115686
Cancer Biother Radiopharm. 2012 Nov;27(9):561-9
pubmed: 23078020
J Histochem Cytochem. 2019 Oct;67(10):735-743
pubmed: 31381461
Eur J Nucl Med. 1999 Nov;26(11):1439-47
pubmed: 10552085
EJNMMI Phys. 2015 Dec;2(1):24
pubmed: 26501825
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Endocrine. 2017 Apr;56(1):146-157
pubmed: 27406390
J Clin Oncol. 2018 Sep 1;36(25):2578-2584
pubmed: 29878866
Semin Nucl Med. 2016 Jan;46(1):40-6
pubmed: 26687856
J Nucl Med. 2019 Jul;60(7):937-943
pubmed: 31263080
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
JAMA Oncol. 2020 Jan 1;6(1):21-22
pubmed: 31697337
Neuroendocrinology. 2020;110(6):517-524
pubmed: 31484182
J Nucl Med. 2020 Feb;61(2):222-227
pubmed: 32015164
J Clin Oncol. 2010 Apr 1;28(10):1652-9
pubmed: 20194865
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
Clin Nucl Med. 2015 Nov;40(11):845-50
pubmed: 26284763
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Clin Cancer Res. 2008 Jun 1;14(11):3555-61
pubmed: 18519789
Clin Nucl Med. 2019 May;44(5):e329-e335
pubmed: 30932975
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382
pubmed: 32123969
J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S
pubmed: 15653647
Theranostics. 2018 May 12;8(12):3308-3316
pubmed: 29930731
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624
pubmed: 28428192
Lancet. 1989 Feb 4;1(8632):242-4
pubmed: 2563413
Cell Cycle. 2007 Feb 1;6(3):364-70
pubmed: 17297293
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):980-990
pubmed: 31912256
J Nucl Med. 2014 Aug;55(8):1248-52
pubmed: 24963127
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
Endocr Relat Cancer. 2018 Apr;25(4):X1-X2
pubmed: 29540494
J Nucl Med. 2021 Jan;62(1):69-72
pubmed: 32444368
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441
pubmed: 29785514
J Nucl Med. 2016 Feb;57(2):260-5
pubmed: 26514177
Neuroendocrinology. 2014;99(2):108-17
pubmed: 24714208
Oncotarget. 2018 May 15;9(37):24693-24706
pubmed: 29872498
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742
pubmed: 30506283
J Nucl Med. 2014 Feb;55(2):183-90
pubmed: 24434296
Clin Lung Cancer. 2019 May;20(3):e376-e392
pubmed: 30910575
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5
pubmed: 1346068
Ann Nucl Med. 2017 Jun;31(5):347-356
pubmed: 28316066
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8
pubmed: 18188559
BMC Gastroenterol. 2018 Jun 15;18(1):84
pubmed: 29902988
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
Ann N Y Acad Sci. 1994 Sep 15;733:416-24
pubmed: 7978890
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717
pubmed: 30267116
Semin Nucl Med. 2002 Apr;32(2):110-22
pubmed: 11965606
Radiother Oncol. 2012 Jan;102(1):45-50
pubmed: 21885142
BMC Cancer. 2017 Aug 8;17(1):528
pubmed: 28789624
Pancreas. 2014 May;43(4):518-25
pubmed: 24632546
Br J Cancer. 2013 Apr 16;108(7):1440-8
pubmed: 23492685
Theranostics. 2016 Jul 18;6(11):1821-32
pubmed: 27570553
Clin Nucl Med. 2017 Nov;42(11):e457-e466
pubmed: 28872545
Clin Cancer Res. 2019 Dec 1;25(23):6939-6947
pubmed: 31439583
Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22
pubmed: 12634971
Exp Oncol. 2013 Jun;35(2):122-6
pubmed: 23828389
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614
EJNMMI Res. 2020 Apr 15;10(1):35
pubmed: 32296955